ForumIAS LATEST
- SFG FRC 2027 | Program starts from 15th Dec. 2026 | Admissions open for Tranche-1 Entrance Test till 25th Oct. 2026 Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 21st October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
- The World Health Organization(WHO) has suggested that Merck’s vaccine (VSV-EBOV) used during the current outbreaks in Congo was 97.5% efficacious in preventing Ebola infection.
- Recombinant vesicular stomatitis virus–Zaire Ebola virus (VSV-EBOV) is an experimental vaccine for protection against Ebola virus disease.
- When VSV-EBOV is injected,the vaccinated individuals generates antibodies against EBOV protein,thereby gaining immunity.
- The vaccine was developed by the Public Health Agency of Canada and licensed to NewLink Genetics.
- In November 2014,Merck entered into a licensing agreement with NewLink Genetics to research,develop,manufacture and distribute the vaccine.
- Ebola virus disease(EVD) formerly known as Ebola haemorrhagic fever, is a severe often fatal illness in humans.The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
